Back to top

Image: Bigstock

Aegerion Pharmaceuticals, Inc.

Read MoreHide Full Article

Aegerion’s second-quarter results were disappointing, with the company reporting a wider-than-expected loss. The company’s lead product Juxtapid is facing challenges with the launch of PCSK9 inhibitors in the U.S. market and will continue to do so in the forthcoming quarters. Further, Juxtapid sales would be hurt by the company’s decision to withdraw the product from the EU. In such a scenario, the company’s merger agreement with QLT Inc. is a big positive. It will leverage Aegerion’s development and commercial capabilities and ability to have a transformative impact on patients suffering from debilitating rare diseases. Aegerion added another drug to its portfolio, Myalept, from AstraZeneca which boosted its portfolio. However, Aegerion is facing reimbursement hurdles for Myalept as prior authorizations are taking longer than expected time and payers are requesting additional data.